The efficacy analysis of simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer
10.3760/cma.j.issn.1008-1372.2017.03.016
- VernacularTitle:同期整合推量调强放疗在局部晚期非小细胞肺癌中的疗效分析
- Author:
Yanfang QIU
;
Wenjuan YANG
;
Zhigang LIU
;
Hui WANG
- Keywords:
Radiotherapy,intensity-modulated;
Carcinoma,non-small-cell lung/RT
- From:
Journal of Chinese Physician
2017;19(3):380-384
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy and toxicity in the use of simultaneous integrated boost intensity modulated radiation therapy (SIB-IMRT) for inoperable locally advanced nonsmall cell lung cancer (LA-NSCLC).Methods Between February 2012 and July 2015,58 pathologically diagnosed inoperable LA-NSCLC patients treated with SIB-IMRT were analyzed.A radiation dose of 50-64 Gy was administered in 1.8-2.2 Gy/fraction (26-30 fractions) to the planning target volume (PTV).Simultaneously,60-70 Gy was administered in 2.0-2.35 Gy/fraction (26-30 fractions) to the planning gross tumor volume (PGTV).Results The median follow-up time was 28.0 months (ranging from 6.0 to 40.0 months).The median overall survival (OS) and progress-free survival (PFS) were 25.0 (95％ CI:23.8-26.2) and 15.0 (95％ CI:11.3-18.7) months,respectively.The 1-,2-year OS were 91.4％ and 51.7％,respectively.The 1-,2-year PFS were 56.9％ and 22.7％,respectively.None of the patients developed grade 4 or 5 pneumonitis and esophagitis.In addition,in the subgroup analysis,the patients with N3 have a higher incident of ≥ grade 2 esophagitis compared with N0-N2,the incident are 29.2％ and 20.6％,respectively (P ＜ 0.05).Conclusions SIB-IMRT is feasible and well-tolerated for inoperable LA-NSCLC patients.It remains to be further evaluated in a large sample size prospective clinical trial.
